期刊
BIOACTIVE MATERIALS
卷 7, 期 -, 页码 292-323出版社
KEAI PUBLISHING LTD
DOI: 10.1016/j.bioactmat.2021.05.038
关键词
Therapeutic oligonucleotides; Nanoparticles; Anti-cancer; Targeted delivery; Clinical translation
资金
- Natural Science Foundation of China [81871472]
- Natural Science Foundation of Guangdong Province [2019A1515010696, 2021A1515012333]
- Shenzhen Municipal Science, Technology and Innovation Commission [JCYJ20190807163003704]
- 100 Talents Program of the start-up foundation from Sun Yat-sen University
- Academy of Finland [328933]
- Sigrid Juselius Foundation
- Academy of Finland (AKA) [328933, 328933] Funding Source: Academy of Finland (AKA)
Therapeutic oligonucleotides (TOs) are promising drug candidates for targeted cancer treatment due to their specificity, but efficient delivery to cancer cells remains a challenge. Nanoparticles (NPs) can protect TOs, enhance their uptake and improve therapeutic index. Stimuli-responsive NPs can minimize toxicity towards normal tissues.
Therapeutic oligonucleotides (TOs) represent one of the most promising drug candidates in the targeted cancer treatment due to their high specificity and capability of modulating cellular pathways that are not readily druggable. However, efficiently delivering of TOs to cancer cellular targets is still the biggest challenge in promoting their clinical translations. Emerging as a significant drug delivery vector, nanoparticles (NPs) can not only protect TOs from nuclease degradation and enhance their tumor accumulation, but also can improve the cell uptake efficiency of TOs as well as the following endosomal escape to increase the therapeutic index. Furthermore, targeted and on-demand drug release of TOs can also be approached to minimize the risk of toxicity towards normal tissues using stimuli-responsive NPs. In the past decades, remarkable progresses have been made on the TOs delivery based on various NPs with specific purposes. In this review, we will first give a brief introduction on the basis of TOs as well as the action mechanisms of several typical TOs, and then describe the obstacles that prevent the clinical translation of TOs, followed by a comprehensive overview of the recent progresses on TOs delivery based on several various types of nanocarriers containing lipid-based nanoparticles, polymeric nanoparticles, gold nanoparticles, porous nanoparticles, DNA/RNA nanoassembly, extracellular vesicles, and imaging-guided drug delivery nanoparticles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据